Recent advances in HER2-targeted inhibitors for cancer therapy.
New antibody-drug conjugates extend HER2-targeted therapy to previously untreatable low-HER2 breast cancers and other tumor types.
This review surveys recent HER2-targeted therapy advances including third-generation ADCs like trastuzumab deruxtecan (T-DXd) that have transformed treatment for HER2-low breast cancer and are being evaluated across multiple tumor types. The expanded definition of HER2 targetability to 'HER2-low' tumors, enabled by high drug-to-antibody ratio ADCs, represents a paradigm shift with major patient population implications.
What the study was
- Study design
- Review
- Category
- Drug Development
- Maturity
- Validated
- Journal
- Pharm Sci Adv
Why it surfaced
HER2 landscape is rapidly evolving with ADC approvals across tumor types; HER2-low targeting is a major precision oncology development; relevant to precision oncology and novel therapeutics watchlists.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.